1.09
+0.0203(+1.90%)
Currency In USD
| Previous Close | 1.07 |
| Open | 1.07 |
| Day High | 1.11 |
| Day Low | 1.06 |
| 52-Week High | 5.85 |
| 52-Week Low | 0.83 |
| Volume | 819,705 |
| Average Volume | 1.12M |
| Market Cap | 85.33M |
| PE | 6.81 |
| EPS | 0.16 |
| Moving Average 50 Days | 1.06 |
| Moving Average 200 Days | 1.5 |
| Change | 0.02 |
If you invested $1000 in CytomX Therapeutics, Inc. (CTMX) since IPO date, it would be worth $84.52 as of December 26, 2024 at a share price of $1.09. Whereas If you bought $1000 worth of CytomX Therapeutics, Inc. (CTMX) shares 5 years ago, it would be worth $123.76 as of December 26, 2024 at a share price of $1.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
GlobeNewswire Inc.
Nov 27, 2024 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and ch
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.
Nov 07, 2024 9:10 PM GMT
- Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. - - Phase 1 study of CX-2051 (EpCAM PROBODY® ADC) in advanced colorectal cancer (CRC) is currently in the fifth dose
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
GlobeNewswire Inc.
Oct 31, 2024 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report third quarter financial res